Vaccine
development
service

• Pre-clinical data of Avacc 11® demonstrated protection against gonorrhea infection • Global incidence rate of this sexual transmitted disease is at 87 million infections per year • OMV technology is a powerful tool to induce protective systemic and mucosal…

• Pre-clinical data of Avacc 11® demonstrated protection against gonorrhea infection • Global incidence rate of this sexual transmitted disease is at 87 million infections per year • OMV technology is a powerful tool to induce protective systemic and mucosal immunity • Data published in the peer reviewed journal MSphere of the American Society of Microbiology

Intravacc launches phase I clinical trial of Avacc 10®, an intranasal subunit booster vaccine for SARS-CoV-2 Bilthoven, The Netherlands, 30 November 2022 –  Intravacc, a world leader in translational research and development of preventive and therapeutic vaccines, today announced that…

• Randomized, double blinded, placebo-controlled trial
• Evaluation of two doses in 36 volunteers
• Mid-term data expected by end Q1 2023

CEPI partners with Intravacc to develop an intranasal, broadly protective Betacoronavirus vaccinee Bilthoven, The Netherlands, 6 October 2022 –  CEPI, the Coalition for Epidemic Preparedness Innovations, and Dutch vaccine clinical development and manufacturing organization Intravacc, today announced the latest funding…